With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
GlaxoSmithKline said the new vaccine to protect against cervical cancer could offer wider resistance to the disease than previously thought, according to new data released yesterday. GSK say that the vaccine, called Cervarix, appeared to be effective against viruses causing 82% of cervical cancer cases following the latest trial among 700 women.
Cervarix had been shown to be effective in blocking two of the most common strains of the papilloma virus, responsible for about 70% of such cancer cases. But according to data presented to a conference in Vancouver yesterday, the treatment in fact works against five HPV strains, raising the drug's effectiveness by a further 12%.
Last week, Gavi, the Vaccine Alliance, completed a $7.5 billion replenishment to fund its work on immunization in the world’s poorest countries between now and 2020. Gavi’s next step is to ensure that the money is used as effectively as possible to save lives and improve health.